ARTICLES BY GUNJAN BAGLA
-
Is Your Intellectual Property Safe With Indian CROs And CDMOs?6/3/2024
Startups and Big Pharma companies alike are considering India as an alternative to working with China. Is it safe to do business with India? Let's do a deep dive, with insights from American and Indian attorneys.
-
India's CROs & CDMOs Come Of Age In The Global Marketplace5/4/2023
Most of the top 10 pharmaceutical companies and many large biotech companies today get a portion of their preclinical/clinical research, drug development, and/or manufacturing done in India. While a low price is the initial attraction, there are additional factors that can be more meaningful.
-
India's Biopharma Innovators Tackle COVID-19 Vaccine Supply Worldwide7/22/2022
This article discusses the roles that Indian biopharmas Serum Institute of India; Biological E, Ltd.; Bharat Biotech; Premas Biotech; and Zydus Cadilla have in supplying North America, Africa, and other regions with COVID-19 vaccines.
-
What Role Will India Play In The Global COVID-19 Vaccine Narrative?1/27/2021
While most Americans are focused on the incredible success of the COVID-19 vaccines developed and produced by Pfizer and Moderna under the $24 billion Operation Warp Speed, there is under-reported news from India that bears a closer look.
-
Pandemic Prompts Supply Chain Exodus From China — What's Best For Your Business?4/27/2020
Decisions made in panic rarely work out for the best. In lieu of abandoning operations in China completely, consider these alternatives to secure your company’s supply chain.
-
India To Regulate All Medical Devices3/25/2020
Expansion of notified device categories is poised to benefit savvy domestic and Western medical device companies by cutting out cut-rate operations.
-
India To Enhance Oversight Of Medical Devices9/25/2019
India's Central Drugs Standard Control Organization (CDSCO), the country’s national regulatory authority for both drugs and medical devices, is forming a new division that works exclusively with medical devices. Here’s what we know so far.
-
Four Ways MedTech Can Thrive In Emerging Markets11/26/2018
Just two percent of the revenues generated by the top 200 medical device companies arise from emerging markets. To achieve greater success, medtech must look beyond the legacy approaches that led to success serving the billion richest patients in the world.
-
Startups Illustrating The Future Of Global Medtech10/17/2018
Globally aware CEOs are looking beyond rich country patients for long-term growth. This article highlights a pair of startups attempting to bring innovation large, under-served populations, and analyzes the effectiveness of their approach.